Alimera Sciences Inc. (ALIM), having achieved encouraging sales results with both Iluvien and Yutiq in the U.S. market in 2023, is buoyed by the sustained high demand observed in its international markets as well.
Iluvien is a non-bioerodable intravitreal implant indicated for the treatment of diabetic macular edema.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com